Smoldering multiple myeloma: taking the narrow over the wide path?
Blood
; 143(20): 2025-2028, 2024 May 16.
Article
en En
| MEDLINE
| ID: mdl-38427775
ABSTRACT
ABSTRACT Smoldering multiple myeloma (MM) is an asymptomatic clonal plasma cell condition considered as a premalignant entity that may evolve over time to symptomatic MM. Based on a "poorly defined" risk of progression, some well-intended investigators proposed prospective interventional trials for these individuals. We believe this may be a harmful intervention and favor a close "wait and watch" approach and rather enroll these patients in dedicated observational biological studies aiming to better identify patients who will evolve to MM, based on their plasma cells' biology, including genomics, epigenetics, and the immune microenvironment.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Mieloma Múltiple Quiescente
Límite:
Humans
Idioma:
En
Revista:
Blood
Año:
2024
Tipo del documento:
Article
País de afiliación:
Francia